Ophthalmic composition comprising an ion-sensitive, hydrophilic polymer and an inorganic salt at a ratio that gives low viscosity

 

(57) Abstract:

This invention relates to ophthalmic compositions in the form of water solution for topical application, consisting mainly of ophthalmologist active agent containing main group ion-sensitive, hydrophilic polymer containing acidic groups in the amount of from 0.004 to 1.5% by weight, of at least one salt selected from the group of inorganic salts and buffers in a total amount from 0.1 to 2.0% by weight, and optionally a wetting agent, a preservative, and the ratio between the salt and the polymer is one that provides the viscosity of the solution is less than 100 MPa, and the pH of the solution is in the range from 4.0 to 8.0. The composition contains an amount of polymer sufficient to provide a controlled absorption of the drug in the eye, while its viscosity is lowered, to provide improved performance for manual manipulation. 9 C.p. f-crystals, 6 ill.

This invention relates to ophthalmic compositions in the form of an aqueous solution for topical application to human and animal health, as well as the use of the solution, in particular, for the treatment of glaucoma and ocular hypertension.

ophthalmic pharmaceuticals and artificial tear compositions (compositions, causing tears). The inclusion of the polymer to increase the viscosity of the composition to provide a longer contact time with the cornea of the eye and, for example, together with ophthalmic drugs to provide prolonged release of the drug in the eye.

For example, the U.S. Patents NN 5075104 and 5209927 relate to ophthalmic gel compositions and ophthalmic liquid composition respectively. The first mentioned composition comprises from 0.25 to 8% by weight carboxy vinyl polymer (polymer carbamatnogo type), the latter includes from 0.05 to 0.25% by weight, the resulting viscosities of the compositions in the range from 15,000 to 300,000, or from 10 to 20,000, respectively.

In the publication WO 93/17664 disclosed viscosity, the polymer-containing ophthalmic composition containing in combination carboxy vinyl polymers carbamatnogo type and cellulose polymers. According to this publication, you can use a lower concentration of polymer to achieve the desired higher viscosity. Identifies a wide range of concentrations of the polymers, the most widely specified range is from 0.05 to 3% by weight of carbomer and from 0.05 to 5% by weight cellulosic polymer and the conditions of pH and temperature of the ocular surface. In this publication it is intended to include up to 0.9% of salt to regulate the viscosity.

In addition, there are a number of publications relating to pharmaceutically active ophthalmic compositions containing various polymers, such as (i. a.), carboxy vinyl polymers at various concentrations. As a regulatory tone of funds is usually assumed nonionic polyols so as not to disturb the gel structure (WO 93/00887, WO 90/13284). In publishing Int. J. Pharm. 81 (1992) 59-65 describes aqueous compositions containing timolol maleate and 0.6% polyacrylic acid (MM 250000), as well as salt base timolol from 0.6% polyacrylic acid containing mannitol as a regulator of tone. It is reported that the viscosity measured at low shear rates, is 45 MPa.

In the description of the DE-patent 2839752 disclosed ophthalmic gel composition containing carboxy vinyl polymers in amounts of from 0.05 to 5.0% by weight and showing a viscosity of from 1000 to 100000 MPa. According to this publication, in order to prevent the destruction of the gel on the surface of the eye, add a small amount of sodium chloride is from 0.001 to 0.5% by weight (see column 4, lines 41ff).

The invention

Datoga type, containing increasing viscosity agents, due to the concentration of polymer present in the composition, not its viscosity. Thus, the purpose of this invention is to develop ophthalmic composition with a sufficiently high concentration of the polymer in order to control the formation of polymer film on the cornea of the eye, but this song is still sufficient liquid for local ophthalmic use. Another purpose of this invention to provide an easy-to-use formulations (formulations) for eye drops with improved convenience for the patient.

According to the invention, it was found that when the concentration of polymer in excess of the value at which the composition is usually more of a gel than a liquid, and while lowering its viscosity it is possible to obtain the desired beneficial effect of active funds on the eyes, compared with the use of a composition in gel form. Indestructible and smooth polymer film, which is formed on the eye, helps to bind and hold water on the surface of the eye and thereby provides additional wetting action, providing better contact and thus controlled absorption of the active funds in the Starting composition, as such, is important from the point of view of obtaining a good absorption of the drug in the eye. This is confirmed, in particular, the tests presented below. In Fig. 3 shows, for example, that when using the same number of polymer compositions that have different viscosities, these songs basically give the same absorbance. According to the state of the art, as would be expected, however, that the required composition with a higher viscosity to allow for greater absorption. These results are confirmed also by the results presented in Fig. 4, which shows that compositions that contain different amounts of polymer, but have the same viscosity and pH, the absorption is stronger in composition with a higher concentration of polymer.

Another important beneficial effect is achieved by using, according to the invention, ophthalmologist active tool, which contains basic groups such as amino groups. This is the main tool involved in ion exchange reactions or formation of salts with the polymer containing acidic groups, such as the polymer is polyacrylic acid. Increased retention of ionic strength between the polymer and the active agent provides additional enhanced delivery of active funds. Due to what about to reduce the daily number of admission medication, if necessary, without loss of activity, and therefore, can also be reduced side effects.

This invention provides an ophthalmic composition in the liquid, easy to use form, which provides both increased and prolonged absorption of the active funds in the eye. Thus, the invention makes possible the treatment of, for example, glaucoma and ocular hypertension using only once a day or less often medical scheme introduction ophthalmic active tool, and makes it possible to lower the dose, certainly below the doses used in the present time.

In particular, the aim of the invention is an ophthalmic composition in the form of locally applied aqueous solution consisting mainly of (% of total composition)

ophthalmic active agents containing basic groups,

ion-sensitive, hydrophilic polymer containing acidic groups in the amount of from 0.004 to 1.5% by weight,

- at least one salt selected from the group of inorganic salts and buffers in a total amount from 0.01 to 2.0% by weight,

- wetting agent in an amount of from 0 to 3.0% by weight,

- preservative in kolichesvto is such which provides the viscosity of the solution is less than 1000 MPa, and the pH of the solution is from 4.0 to 8.0.

A detailed description of the invention

Ion-sensitive hydrophilic polymer to be used according to the invention contains an acidic group and usually represents a carboxy vinyl polymer or hialuronowy acid. Typical representatives of carboxy vinyl polymers are polymers of polyacrylic acid, known as carbomer. Suitable carbomer different molecular masses, usually in the range of, for example, from 450000 to 4000000 and supplied under the trade name Carbopol, for example Carbopol 907, 910, 934, 934P, 940, 941, 971, 971P, 974, 974P, 980 and 981, preferably Carbopol 941 and 981.

The polymer preferably used in quantities of from 0.01 to 0.8, more preferably from 0.01 to 0.4, and preferably from 0.04 to 0.4% by weight.

According to the invention, it was found that favorable from the point of view of the effectiveness of the product in place of the target, and ease of use is lowering the viscosity of the composition to less than 1000 MPa, suitable less than 800 MPa, measured at 25oC using type viscometer Brookfield LVDV-111 at the shear rate D of 1.1 with-1. This goal is achieved by time to relax is at. As decreasing the viscosity of salts and buffers can be mentioned the following: sodium chloride, potassium chloride, sodium phosphate (monobasic and Dwuosobowy), sodium borate, sodium acetate, sodium citrate, cash equivalents or mixtures thereof. When salt is not added, get the formulation (recipe) with unacceptably high viscosity. It should be noted that the proposed composition still shows the favorable non-Newtonian properties when used on the surface of the eye, despite the addition of salts.

For some purposes, for example in order to preserve the appearance of and storage, use of buffer salts are preferably used, for example, sodium chloride or potassium as reducing the viscosity of the agent.

Suitable pH for the composition is in the range from 5.0 to 8, preferably from 6.5 to 8.0. the pH of the composition according to the invention is established only through the quantities used acidic polymer and a basic active means, respectively, and in such cases no additional pH-regulating agent. This in turn means that the method of obtaining the composition can be simplified.

Ophthalmologist active tool predpochtite is to - blocker, carbonic anhydrase inhibitor, or an antibiotic, anti-inflammatory, antiallergic drug, etc., containing a basic group, or a combination thereof. Thus, according to the invention, the alleged eye medicines can contain primary, secondary or tertiary amino group or organoammonium or amidin attached to the chain or ring, or atom(s) of the nitrogen may be part of different basic heterocycles, such as imidazole, imidazoline, pyridine, piperidine or piperazine. Preferably use the tool that is active against glaucoma or effective for the treatment of elevated intraocular pressure. A particularly preferred group of compounds are blocking means having a secondary amine function, such as betaxolol, carteolol, levobunolol, metipranolol, pindolol, propranolol and timolol in primary form. Particularly preferred form of the invention is the manner in which the use of timolol in the form of its easy kristallicheskogo S-timolol hemihydrate.

Other typical examples of molecules of essential medicines used in the treatment of eye include tobramycin and norfloxacin (antimicrobial, proteobacterial, carbachol, echothiophate (cholinergic), epinephrine, dipivefrin, dopamine (adrenergic), nafazolina, tetryzoline (vasoconstrictor), verapamil, nifedipine (vasodilator), apraclonidine, clonidine, medetomidin (2agonist), setlimit (carbonic anhydrase inhibitor), cetirizine (antihistamine), as such or in the form of ester in the form of preprepared.

Particularly close attention in the invention focuses on the use of the blocking means, such as S-timolol, especially in the form of a hemihydrate, as a single drug or in combination with, for example, the main form of pilocarpine.

The number of active funds in the final composition can be varied, for example, in the range from 0.001 to 5% by weight, usually, however, from 0.01 to 0.5% by weight and typically from 0.1 to 0.5% by weight, especially in the case of S-timolol hemihydrate.

According to a preferred variant embodiment of the invention, the composition further comprises, with the aim of improving its wetting action, wetting agent, preferably a polyhydric alcohol such as glycerin. The quantity of wetting agent is usually the greater of 3.0%, for example about 0.5 to 3.0% by weight.

The preferred composition is in the form of an aqueous solution mainly consists of the following components (% is wt% calculated on the total weight of the composition):

- timolol in the form of its hemihydrate in an amount of from 0.1 to 0.5% by weight, calculated on a free base.

- polyacrylic acid in amount of from 0.04 to 0.4% by weight,

glycerin in an amount of from 0.5 to 2.5% by weight,

- phosphates of sodium in amounts of from 0.01 to 1.5 by weight,

a preservative in an amount of from 0 to 0.02% by weight and

- water,

moreover, the viscosity of the composition is less than 800 MPa and the pH of the composition is in the range from 6.5 to 8.

According to the invention, the term "consisting mainly of" as referring to means that the composition contains only or mostly only components that are listed in connection with it. The composition can, however, also contain substances such as ophthalmologist acceptable AIDS and additives of such type and in such quantities that do not have a significant impact on the performance of the composition.

The proposed composition of alibabki in the autoclave. In the second stage, other ingredients, namely the active ingredient(s), inorganic salt(s) regulating the tone of the agent(s), preservatives or any other additives, are dissolved in sterile water and sterilized by filtration on a filter (pore size, for example, 0.2 μm). The third and last stage, the solution is obtained in two stages, aseptically combined and stirred until then, until it forms a homogeneous solution with low viscosity. the pH of the solution is usually adjusted by adding the relative amounts of the active drug and the polymer. Then the composition is Packed in the form of multi - or single doses.

The following examples illustrate the invention in more detail, without limiting it.

Example 1

Get the following composition:

Composition (g)

S-timolol hemihydrate - 2,56

Carbopol 941 - 0,95

Sodium phosphate monoosnoc - 0,08

Sodium phosphate Dwuosobowy - 1,80

Glycerin - 23,0

Benzalkonium chloride - 0,06

Water for injection to 1000 ml

Carbopol 941 was dispersed in 300 ml of sterile water at room temperature. The solution is sterilized in an autoclave. Autoclaved solution is cooled to room temperature (solution 1). Benzenering water at room temperature and sterilized by filtration on a filter pore size of 0.2 μm (solution 2). At the final stage, the solutions obtained in the previous two stages (solutions 1 and 2), aseptically combined and stirred until then, until it forms a homogeneous solution with low viscosity. the pH of the resulting solution is equal to 7.4 and a viscosity of 440 MPa (D = 1,1-1). Then the solution is Packed in a traditional bottle of eye drops.

The curve of viscosity depending on shear rate for the composition shown in Fig. 1. It should be noted that the shape of the curve still shows non-Newtonian rheology, in spite of additive salts.

Example 2

Get the following composition:

Composition (g)

S-timolol hemihydrate - 2,56

Carbopol 941 - 0,85

Sodium chloride 0,9

Glycerin - 20,0

Benzalkonium chloride - 0,06

Water for injection to 1000 ml

Solution get according to example 1. the pH of the resulting solution is 6.9 and the viscosity of the solution was 380 MPa {D = 1,1-1). The curve of viscosity depending on shear rate is shown in Fig. 1.

Example 3

Get the following composition:

Composition (g)

S-timolol hemihydrate - 2,56

Carbopol 981 - 1,4

Sodium phosphate monoosnoc - 0,62

Sodium phosphate Dwuosobowy - 2,85

Glycerin - 23,0
-1). The curve of viscosity depending on shear rate is shown in Fig. 1.

Example 4

Get the following composition;

Composition (g)

S-timolol hemihydrate - 1,0

Carbopol 981 - 0,65

Sodium phosphate monoosnoc - 0,016

Sodium phosphate Dwuosobowy - 0,32

Glycerin - 23,0

Benzalkonium chloride - 0,06

Water for injection to 1000 ml

Solution get according to example 1. the pH of the resulting solution is equal to 6.6. The viscosity of the solution amounted to 540 MPa (D = 1,1-1).

Example 5

Get the following composition:

Composition (g)

S-timolol hemihydrate - 2,56

Carbopol 941 - 2,0

Sodium phosphate monoosnoc - 1,40

Sodium phosphate Dwuosobowy - 7,42

Glycerin is 16.0

Benzalkonium chloride - 0,06

Water for injection to 1000 ml

Solution get according to example 1. the pH of the resulting solution is 6.9 and the viscosity of the solution was 600 MPa (D = 1,1-1).

Example 6

Get the following composition:

Composition (g)

S-timolol hemihydrate - 5,12

Carbopol 981 - 3,0

Sodium phosphate monoosnoc - 2,0

Sodium phosphate Dwuosobowy - 10,0

Glycerin - 5,0

Benzalkonium chloride - 0,07

Water for injection to 1000 ml

Solution ol>).

Example 7

Get the following composition:

Composition (g)

Clonidine (base) - 1,25

Carbopol 981 - 0,70

Sodium phosphate monoosnoc - 0.04

Sodium phosphate Dwuosobowy - 0,6

Glycerin - 23,0

Benzalkonium chloride - 0,06

Water for injection to 1000 ml

Solution get according to example 1. the pH of the resulting solution is equal to 7.0 and a viscosity of the solution amounted to 540 MPa (D = 1,1-1).

Example 8

Get the following composition:

Composition (g)

Pilocarpine (base) - 20,0

Carbopol 981 - 3,0

Sodium phosphate monoosnoc to 10.6

Sodium phosphate Dwuosobowy - 0,53

Glycerin - 5,0

Benzalkonium chloride - 0,10

Water for injection to 1000 ml

Solution get according to example 1. the pH of the resulting solution is equal to 6.8 and a viscosity of the solution was 900 MPa (D = 1,1-1).

Not given in the formulations (examples 1-8) benzalkonium chloride, get formulations corresponding standard dose.

Absorption of timolol in the eye of the rabbit (Study 1)

Ophthalmic formulations (example 1), which is a typical example of the present invention, the fluid to rabbit eyes (n = 6). The concentration of timolol in ocular opol, of timolol and preservative, benzalkonium, but did not contain any inorganic salt(s). The viscosity of the product in comparison was much higher (7300 MPa, D = 1,1-1). The curves of viscosity of the products is shown in Fig. 2. The concentration of timolol in the aqueous humor in rabbits is shown in Fig. 3. According Fig. 3, the absorption of timolol in the eye of rabbits was similar, despite different viscosities.

Absorption of timolol in the eye of the rabbit (Study 2 and 3)

Solutions timolol buried in the eyes of the rabbit. Input solutions timolol had the same pH and the same viscosity, but the solutions contained different amounts of polyacrylic acid (Carbopol 941). The concentration of timolol was determined after 1/2 hour and 1 hour using ghvd (HPLC). The concentration of timolol in the aqueous humor in rabbits is shown in Fig. 4 and 5. According Fig. 4 and 5, the absorption of timolol in the eye of rabbits depends on the concentration of polymer used.

The stability of the solution timolol-polyacrylic acid

Ophthalmic formulations (example 1), which represents a typical formulation of the present invention, stored at room temperature for 12 months. The viscosity of the solution timolol-poliakrilovye temperature. The curves of viscosity depending on shear rate is shown in Fig. 6. The results show that the viscosity of the solution timolol-polyacrylic acid remains stable even after one year of storage.

1. Ophthalmic composition in the form of an aqueous solution for topical application, consisting mainly of ophthalmologist active agent containing basic groups in an amount of from 0.001 to 5% by weight, ion-sensitive, hydrophilic polymer containing acidic groups in the amount of from 0.004 to 1.5% by weight, of at least one salt selected from the group of inorganic salts and buffers in a total amount from 0.01 to 2.0% by weight of the wetting agent in an amount of from 0 to 3.0% by weight, a preservative in an amount of from 0 to 0.02% by weight, and water, whereby the ratio between the salt component and polymer component is such that provides a viscosity of the solution is less than 1000 MPa, and the pH of the solution is from 4.0 to 8.0.

2. Composition under item 1, in which the polymer is present in amounts of from 0.01 to 0.8%, preferably from 0.01 to 0.4% and preferably from 0.04 to 0.4% by weight and selected from the group consisting of CARBOROL 907, 910, 934, 934P, 940, 941, 971, 971P, 974, 974P, 980 and 981.

3. Composition under item 1 or 2,in amount ranging from 0.5 to 2.5% by weight.

5. Composition according to any one of the preceding paragraphs, in which the salt is selected from the group consisting of sodium chloride, potassium chloride, sodium phosphate, sodium borate, sodium acetate, sodium citrate and cash equivalents and mixtures thereof, and that it is present, especially in quantities of from 0.01 to 1.5% by weight.

6. Composition according to any one of the preceding paragraphs, in which its viscosity is less than 800 MPa.

7. Composition according to any one of the preceding paragraphs, having a pH range of 5.0 to 8.0, preferably 6.5 to 8.0.

8. Composition according to any one of the preceding paragraphs, in which the ophthalmologist active agent selected from the group consisting of protivoglaucomny funds, sympathomimetic funds, sympatholytic tools such as-blockers, carbonic anhydrase inhibitors, antibiotics, anti-inflammatory, antiallergic agents, and combinations thereof.

9. The composition according to p. 8, in which the active agent is chosen from the group consisting of betaxolol, carteolol, levobunolol, metipranolol, pindolol, propranolol and timolol, as well as their mixtures with pilocarpine, especially S-timolol hemihydrate.

10. The composition according to p. 1, consisting mainly of TimorLeste from 0.04 to 0.4% by weight, glycerin in an amount of from 0.5 to 2.5% by weight, of sodium phosphate in amounts of from 0.01 to 1.5% by weight, a preservative in an amount of from 0 to 0.02% by weight, and water, whereby the viscosity of the solution is less than 800 MPa and pH of the solution is in the range from 6.5 to 8.0.

 

Same patents:

The invention relates to medicine and can be used for the treatment of acute poisoning with organophosphorus substances
The invention relates to medicine and can be used for preoperative preparation of patients

The invention relates to medicine, namely to toxicology, and can be, in particular, used for the treatment of acute poisoning

The invention relates to the field of veterinary medicine, in particular veterinary gynecology, and can be used for the prevention and treatment of postpartum endometritis

The invention relates to medicine, in particular to a gastroenterologist, and for the treatment of erosions and ulcers, gastroduodenal
The invention relates to medicine, more specifically to surgery and anesthesia, and may find application in the treatment of parenchymal respiratory failure
The invention relates to medicine, abdominal surgery, can be used to treat inflammation in the area of anastomosis after gastrectomy
The invention relates to medicine, in particular to the field of ophthalmology, and for the preparation of soft contact lenses for use
The invention relates to medicine and for the treatment of diabetic angiopathy

FIELD: medicine, surgical stomatology.

SUBSTANCE: in case of patient's average-severe or severe state before surgical interference or at satisfactory state - after surgical interference one should intravenously once introduce perfluorane at the dosage of 1-3 ml/kg body weight followed by daily treatment of the wound with perfluorane, washing and introducing perfluorane-impregnated gauze tampons till the end of exudation phase. The method enables to widen the number of preparations to treat odontogenic phlegmons of oral area, simplify therapeutic technique due to excluding the work with patient's blood, accelerate the process of purification and regeneration of soft tissues in the region of inflammation and shorten therapy terms.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine.

SUBSTANCE: method involves introducing perfluoran bubbled with ozone-and-oxygen mixture with given ozone concentration of 3000 mkg/l during 15 min.

EFFECT: restricted peritoneal inflammation.

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating different wounds. The suggested perfluorocarbon emulsion is being used as the medium in case of ultrasound treatment of wounds. Moreover, the enhancement of reparative processes is observed in the wound along with accelerated wound healing due to development of perfluorophages in area of inflammatory process and to higher gas saturation of perfluorocarbon emulsion against other media applied before. The emulsion under the action of low-frequency ultrasound obtains other properties (increased specific weight, increased fluidity, higher wettability of purified surface, the presence of abrasive properties) necessary for achieving technical result. All these measures, thus, enhance reparative processes in the wound because low-frequency ultrasound raise to a higher power the action of perfluorocarbon emulsion both regarding ultrasound purification and its curative action upon wound.

EFFECT: higher efficiency.

5 dwg, 1 ex

FIELD: cosmetology, dermatology.

SUBSTANCE: the present innovation deals with applying preparations affecting the values of blood microcirculation in skin. The suggested preparation is the emulsion of perfluorocarbons that increases skin resistance to negative impacts and favorably affects microcirculation by steadily increasing its total level that enables to improve the state of microcirculatory canal of skin.

EFFECT: higher efficiency.

6 dwg

FIELD: medical engineering.

SUBSTANCE: method involves exposing an intraocular neoplasm after vitrectomy and retinotomy, smoothening retina with perfluororganic compound later substituted with silicon oil. After having removed the neoplasm, intravenous 10% Perfluorane emulsion transfusion is carried out at a rate of 60 drops per 1 min in the amount of 80-100 ml. Next to it, photosensitizer is intravenously drop-by-drop introduced into cubital vein of the same arm. Laser irradiation of blood is carried out with power of 20-50 mW through laser light guide set in advance into cubital vein of the other arm in 5-15 min after starting introducing Perfluorane. When applying 0.1-1% water solution of Khlorine as photosensitizer at a dose of 0.2-0.5 mg/kg, irradiation is carried out at wavelength of 630-633 nm during 10-45 min. The treatment is administered twice with 5 days long pause.

EFFECT: enhanced effectiveness of treatment; reduced risk of tumor cells dissemination and metastases formation.

3 cl

FIELD: medicine.

SUBSTANCE: the suggested emulsion contains quickly excreting perfluoroorganic compounds as perfluorodecalin and perfluorooctylbromide, perfluoroorganic additive and phospholipids in the form of dispersion prepared due to homogenization at pressure of not less than 100 atm. in water-saline medium. Perfluoroorganic additive is being the mixture of perfluorated tertiary amines - perfluorotripropylamine and its co-products: cis- and trans-isomers of perfluoro-1-propyl-3.4-dimethylpyrrolidone and perfluoro-1-propyl-4-methylpiperidine. The method to obtain the emulsion deals with obtaining the dispersion of phospholipids due to homogenization at pressure of not less than 100 atm. in water-saline medium followed by thermal sterilization, then comes homogenization at pressure of the mentioned perfluoroorganic compounds in dispersion of phospholipids and thermal sterilization of the ready-to-use emulsion. The latter is indicated to treat blood losses, hypoxic and ischemic states, improve oxygen supply by blood and keep isolated perfused organs and tissues. In accordance to the present innovation stability of emulsion has been increased and its qualities have been improved. Storage period of emulsion in its unfrozen state at +4 C corresponds to 12 mo, not less, moreover, biocompatibility of emulsion with biological medium (blood, plasma or serum)has been kept.

EFFECT: higher efficiency of application.

20 cl, 13 ex, 21 tbl

FIELD: cosmetology, dermatology.

SUBSTANCE: the suggested aqueous emulsion of perfluorocompounds contains perfluorocompounds, water and emulsifier, additionally it may contain emulsion wax, moreover, as an emulsifier it contains block-copolymer of ethylene oxides and propylene, components should be taken at certain ratio. Method for obtaining aqueous emulsion deals with mixing aqueous solution of emulsifier and emulsion wax while heating in necessary quantities, cooled mass should be supplemented with perfluorocompounds at constant mixing with ultra-mixer at the rate of 15000 rot./min to homogenize then the mixture obtained, one should perform 3-5 cycles at pressure not exceeding 600 bar. The suggested method enables to obtain the emulsion of high stability and obtain wide-range spectrum of products for cutaneous application.

EFFECT: higher efficiency of application.

3 cl, 1 dwg, 6 ex, 2 tbl

FIELD: infectious diseases and surgery.

SUBSTANCE: wound surface is covered with perfluorane porcine spleen perfusate. Application is repeated daily over a period of 4-12 days depending on the wound surface area and virulence of causative agent. Perfluorane porcine spleen perfusate is prepared by passing perfluorane through spleen vessels at velocity 20-40 ml/min and total volume up to 1 L. Perfusate is used in amount 0.5-0.7 ml per 1 cm2 wound surface area.

EFFECT: activated local immunity and tissue oxygenation.

2 ex

FIELD: medicine, anesthesiology, resuscitation.

SUBSTANCE: under conditions of artificial pulmonary ventilation at positive pressure at the end of expiration one should set the level of positive pressure at the end of expiration being above against pre-chosen optimal one for 4-8 cm water column. About 10-15 min later one should introduce perfluorocarbon as aerosol with the help of nebulizer for 10-15 min. The innovation enables to introduce perfluorocarbons without depressurization of respiratory contour, decreases damaging impact upon pulmonary parenchyma and, also, reduce invasiveness of the method and decrease expenses of perfluorocarbons.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, traumatology.

SUBSTANCE: one should puncture the wound with perfluorane at the dosage of 30 ml, not more/kg affected area once daily for 14 d, not more. The present innovation provides prophylaxis of reperfusion and purulent-necrotic complications in case of gunshot wounds and that of anaerobic infection due to oxygen supply to ischemized wound tissues at adequate quantity during pre-hospital period.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to 1-ethanolamide PGF of formula I useful in relaxation of mammalian intraocular pressure. Claimed substance unlike majority of ocular hypotensive prostaglandins doesn't effect through FP-receptor.

EFFECT: new effective compound for relaxation of mammalian intraocular pressure.

4 cl, 1 ex, 16 dwg, 16 tbl

Up!